Rapport Therapeutics (NASDAQ:RAPP) Given New $46.00 Price Target at Wells Fargo & Company

Rapport Therapeutics (NASDAQ:RAPP) had its price target hoisted by Wells Fargo & Company from $43.00 to $46.00 in a research report released on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

A number of other research analysts have also issued reports on RAPP. HC Wainwright raised their price objective on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, BTIG Research boosted their price objective on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a research note on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Rapport Therapeutics Stock Up 3.1%

Shares of RAPP stock opened at $30.54 on Wednesday. Rapport Therapeutics has a twelve month low of $7.73 and a twelve month high of $42.27. The stock’s fifty day simple moving average is $28.14 and its 200 day simple moving average is $26.89. The firm has a market capitalization of $1.46 billion, a P/E ratio of -10.68 and a beta of 1.51.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07). As a group, equities research analysts expect that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Insider Buying and Selling

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the sale, the insider owned 387,075 shares of the company’s stock, valued at approximately $11,232,916.50. This represents a 2.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Cheryl Gault sold 2,014 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total transaction of $58,265.02. Following the transaction, the chief operating officer owned 169,914 shares of the company’s stock, valued at approximately $4,915,612.02. The trade was a 1.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 69,669 shares of company stock valued at $1,999,877. Insiders own 13.57% of the company’s stock.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in Rapport Therapeutics by 69.1% in the fourth quarter. Invesco Ltd. now owns 267,120 shares of the company’s stock valued at $8,104,000 after buying an additional 109,136 shares during the period. XTX Topco Ltd acquired a new stake in Rapport Therapeutics during the 4th quarter worth about $396,000. Vestal Point Capital LP raised its position in shares of Rapport Therapeutics by 16.8% in the 4th quarter. Vestal Point Capital LP now owns 1,110,000 shares of the company’s stock worth $33,677,000 after acquiring an additional 160,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Rapport Therapeutics in the 4th quarter valued at about $268,000. Finally, Perceptive Advisors LLC lifted its stake in shares of Rapport Therapeutics by 66.8% in the 4th quarter. Perceptive Advisors LLC now owns 673,923 shares of the company’s stock valued at $20,447,000 after purchasing an additional 270,000 shares during the period.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Wells Fargo raised its price target to $46 and kept an “overweight” rating, highlighting upside (~50.6% from the referenced price) and likely contributing to bullish sentiment. Benzinga
• Positive Sentiment: H.C. Wainwright reiterated a Buy and set a $40 price target, citing RAP‑219 program progress and 2026 catalysts — another analyst vote of confidence supporting the rally. TipRanks
• Positive Sentiment: Rapport announced a strategic collaboration and license with Tenacia Biotechnology to develop and commercialize RAP‑219 in Greater China — the deal adds regional commercialization optionality and non‑dilutive funding potential (coverage referenced as a multi‑hundred million biobucks structure). FinanzNachrichten
• Positive Sentiment: Company FYE results and business update: RAP‑219 showed robust Phase 2a activity, Phase 3 initiation is expected in Q2 2026, pipeline expansion (PGTCS, bipolar mania) continues, and cash of ~$490.5M is expected to fund operations into H2 2029 — this reduces financing risk and supports valuation. GlobeNewswire
• Neutral Sentiment: COO Cheryl Gault sold ~2,014 shares (small, ~1.17% reduction of her position) — routine insider selling but disclosed; investors may note timing/size but it’s not large enough to materially change ownership structure. SEC filing
• Negative Sentiment: Reported quarterly EPS of ($0.72) missed consensus of ($0.65), a short‑term negative on earnings momentum that could temper sentiment until Phase 3 execution and trial readouts provide fresh catalysts. Press release / results

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.